Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - atazanavirsulfat - kapsler, hårde - 150 mg

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - atazanavirsulfat - kapsler, hårde - 300 mg

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - atazanavirsulfat - kapsler, hårde - 200 mg

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - atazanavirsulfat - kapsler, hårde - 300 mg

Evrópusambandið - danska - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv infektioner - antivirale midler til systemisk anvendelse - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Danmörk - danska - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - atazanavirsulfat - kapsler, hårde - 300 mg

Evrópusambandið - danska - EMA (European Medicines Agency)

gilead sciences ireland uc - cobicistat - hiv infektioner - antivirale midler til systemisk anvendelse - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Evrópusambandið - danska - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabine, tenofovir alafenamide, fumarate - hiv infektioner - antivirale midler til systemisk anvendelse - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (se afsnit 5.

Evrópusambandið - danska - EMA (European Medicines Agency)

takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.

Evrópusambandið - danska - EMA (European Medicines Agency)

takeda gmbh - pantoprazol - gastroøsofageal tilbagesvaling - proton pumpe hæmmere - kortvarig behandling af reflukssymptomer (f.eks. halsbrand, syreregurgitation) hos voksne.